21 Feb

Prime Nordic plc is delighted to announce an investment into the Swedish Biopharmaceutical Company, Genovis.  Based at the esteemed Medicon Village, the life science research park in Lund, Genovis provides unique enzymes and technologies for analytical characterisation and conjugation of biopharmaceuticals.

About Genovis

Genovis was founded in 1999 by Sarah Fredriksson where she acted as the CEO until May 2015 after which she went on to be chairman of the board. Initially, the business mainly focused on nanoparticles (NIMT®) intended for both the preclinical and clinical markets. Beginning around 2010, the company launched advanced unique enzymes for analysis of biological drugs, and antibodies particularly for therapeutic use. The enzyme portfolio grew and more enzymes in various formats have been added since then. In 2015 Genovis streamlined its operations to specialise in development, production and sales of enzymes for the growing global pharmaceutical industry that works on developing biologicals for the future.

Genovis’ business concept is to offer customers in the pharmaceutical and medical device industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

Overarching Goals

  • Genovis will increase knowledge about biological processes that enable new and effective treatments and medicines.
  • Genovis will establish its products as the solution of choice in all analyses, from early discovery to production of tomorrow’s medications.
  • Genovis will create long-term shareholder value through results that generate both dividends for shareholders and funding for the continued innovative development of the Company.

Operational Strategy

  • Offer innovation combined with high quality through internal development by working close to the frontlines of research and by nurturing relationships with prestigious research groups, as well as by actively seeking new technologies through the acquisition of intellectual property or companies.
  • Genovis will work closely with customers to implement the enzymes in analysis procedures from drug discovery, through clinical trials to production control of the customer's drug candidate throughout its lifetime.
  • Genovis will be an innovative company and an attractive workplace that takes advantage of staff expertise and offers all employees the opportunity to influence their work situation and professional development.

With co-shareholders including Avanza Pension, Nordnet Pension, Handelsbanken & Goldman Sachs, Prime Nordic is proud to become an investor into a company providing a positive impact to the development of biopharmaceuticals, alongside a clear and driven potential for capital growth.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Growth Market under the ticker GENO, and Erik Penser Bank is the Company’s Certified Adviser.

* The email will not be published on the website.